Holen Sie sich die Stockscreener-App
8.58
4.03%
-0.36
Schlusskurs vom Vortag:
$8.94
Offen:
$8.98
24-Stunden-Volumen:
2.24M
Relative Volume:
6.13
Marktkapitalisierung:
$157.10M
Einnahmen:
$137.27M
Nettoeinkommen (Verlust:
$-123.57M
KGV:
-0.7789
EPS:
-11.016
Netto-Cashflow:
$-102.89M
1W Leistung:
+37.06%
1M Leistung:
+8.47%
6M Leistung:
+92.81%
1J Leistung:
-6.18%
1-Tages-Spanne:
$8.11
$9.45
1-Wochen-Bereich:
$5.90
$9.9399
52-Wochen-Spanne:
$3.51
$10.38
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Firmenname
Karyopharm Therapeutics Inc
Sektor
Branche
Telefon
617-658-0600
Adresse
85 WELLS AVENUE, NEWTON, MA
Compare KPTI vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
8.58 | 163.69M | 137.27M | -123.57M | -102.89M | -11.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-05 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-10-13 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-07-16 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-07-11 | Fortgesetzt | H.C. Wainwright | Buy |
| 2023-01-19 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-11-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-08-06 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-07-23 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-07-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-05 | Bestätigt | Robert W. Baird | Outperform |
| 2019-03-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-02-28 | Bestätigt | BofA/Merrill | Underperform |
| 2019-02-27 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | Eingeleitet | B. Riley FBR | Buy |
| 2018-11-09 | Hochstufung | Wedbush | Neutral → Outperform |
| 2018-05-24 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-04-02 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-11-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2016-09-08 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-30 | Hochstufung | Jefferies | Hold → Buy |
| 2016-08-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-06-28 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Karyopharm Therapeutics Inc Aktie (KPTI) Neueste Nachrichten
Is Karyopharm Therapeutics Inc.’s growth already priced in2025 Market Outlook & Daily Profit Focused Stock Screening - mfd.ru
Karyopharm Therapeutics Faces Rising Regulatory and Political Risks Amid Supreme Court Limits on FDA Authority - TipRanks
Karyopharm Earnings Call: Pivotal Data Amid Cash Squeeze - TipRanks
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2025 Earnings Call Transcript - Insider Monkey
Karyopharm Therapeutics Inc. SEC 10-K Report - TradingView
Karyopharm Q4 2025 slides: Revenue growth amid pivotal myelofibrosis readout preparations - Investing.com Canada
Karyopharm Therapeutics Inc Shares Rise After Q4 2025 Results - AlphaStreet News
Karyopharm Therapeutics Inc (KPTI) Q4 2025 Earnings Call Highlig - GuruFocus
Karyopharm Therapeutics Q4 Earnings Call Highlights - MarketBeat
Karyopharm reports fourth quarter and full year 2025 financial results and highlights recent company progress - marketscreener.com
Karyopharm Therapeutics (NASDAQ:KPTI) Announces Earnings Results, Misses Expectations By $3.45 EPS - MarketBeat
Page not foundAirwhon - MarketBeat
Karyopharm (KPTI) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Karyopharm sees 11.8% revenue rise in Q4 2025 - Investing.com India
Karyopharm Q4 2025 slides: Revenue growth amid pivotal myelofibrosis readout preparations By Investing.com - Investing.com India
KPTI: Q4 revenue up, operating loss improved, pivotal phase 3 data in myelofibrosis due soon - TradingView
Karyopharm Therapeutics: Fourth Quarter Earnings Overview - Bitget
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Karyopharm Therapeutics Inc (NASDAQ:KPTI) Reports Q4 Revenue Miss and Wider Loss, Stock Falls in Pre-Market - ChartMill
KARYOPHARM THERAPEUTICS ($KPTI) Releases Q4 2025 Earnings - Quiver Quantitative
Karyopharm Therapeutics: Q4 Earnings Snapshot - WWLTV.com
Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress - Karyopharm
Karyopharm Reports 2025 Financials and 2026 Outlook - Intellectia AI
Uncovering Potential: Karyopharm Therapeutics's Earnings Preview - Benzinga
Can Karyopharm Therapeutics Inc. benefit from deglobalizationIPO Watch & Safe Capital Growth Plans - mfd.ru
Investment Report: Can Karyopharm Therapeutics Inc disrupt its industry2025 Earnings Surprises & Low Risk High Reward Ideas - baoquankhu1.vn
Stock Market Recap: Can Karyopharm Therapeutics Inc disrupt its industryTrade Performance Summary & Risk Managed Investment Entry Signals - baoquankhu1.vn
Karyopharm Therapeutics (KPTI) Expected to Announce Earnings on Thursday - MarketBeat
Karyopharm Therapeutics (KPRX): Tiny Cancer Stock, Massive Drama – Is It Worth Your Money? - AD HOC NEWS
Cantor Fitzgerald Initiates Coverage on KPTI with Overweight Rat - GuruFocus
Cantor Fitzgerald initiates Karyopharm stock with Overweight rating By Investing.com - Investing.com South Africa
Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 - Karyopharm
Cancer drug maker Karyopharm to detail 2025 results in Feb. 12 call - Stock Titan
Cantor Fitzgerald Initiates Coverage on Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat
Cantor Fitzgerald initiates Karyopharm stock with Overweight rating - Investing.com India
Karyopharm Therapeutics reports inducement grants under Nasdaq Listing Rule - marketscreener.com
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
FOMO Trade: How sensitive is Karyopharm Therapeutics Inc to inflationJuly 2025 Highlights & High Accuracy Investment Signals - baoquankhu1.vn
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Up 110.2% in January - Defense World
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Update - MarketBeat
Abate, Karyopharm Therapeutics CAO, sells $351 in stock By Investing.com - Investing.com South Africa
Abate, Karyopharm Therapeutics CAO, sells $351 in stock - Investing.com
Portfolio Update: mơ công an bắt xeQuarterly Earnings Report & Proven Capital Preservation Methods - baoquankhu1.vn
Karyopharm Therapeutics (NASDAQ:KPTI) Shares Pass Below 50-Day Moving AverageHere's What Happened - MarketBeat
Can Karyopharm Unlock Xpovio's Growth In 2026 With Pivotal Myelofibrosis Data Ahead? - RTTNews
How New Price Targets Are Shaping The Story For Karyopharm Therapeutics (KPTI) - Yahoo Finance
Abate, Karyopharm Therapeutics CAO, sells $1.6k in stock By Investing.com - Investing.com UK
Finanzdaten der Karyopharm Therapeutics Inc-Aktie (KPTI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Karyopharm Therapeutics Inc-Aktie (KPTI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Abate Kristin | Chief Accounting Officer |
Jan 28 '26 |
Sale |
7.03 |
50 |
352 |
22,622 |
| Abate Kristin | Chief Accounting Officer |
Jan 21 '26 |
Sale |
5.96 |
265 |
1,579 |
22,580 |
| Abate Kristin | Chief Accounting Officer |
Oct 01 '25 |
Sale |
6.30 |
362 |
2,279 |
10,046 |
| Paulson Richard A. | President and CEO |
Sep 15 '25 |
Sale |
6.43 |
1,257 |
8,083 |
84,046 |
| Mano Michael | SVP, General Counsel&Secretary |
Sep 15 '25 |
Sale |
6.43 |
234 |
1,505 |
21,425 |
| Poulton Stuart | EVP, Chief Development Officer |
Sep 15 '25 |
Sale |
6.43 |
401 |
2,578 |
27,710 |
| Rangwala Reshma | EVP & Chief Medical Officer |
Sep 15 '25 |
Sale |
6.43 |
408 |
2,623 |
29,390 |
| Cheng Sohanya Roshan | EVP & Chief Commercial Officer |
Sep 15 '25 |
Sale |
6.43 |
325 |
2,090 |
35,856 |
| Abate Kristin | Chief Accounting Officer |
Sep 15 '25 |
Sale |
6.43 |
23 |
148 |
10,408 |
| Abate Kristin | Chief Accounting Officer |
Sep 03 '25 |
Sale |
6.78 |
12 |
81 |
9,463 |
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):